Results 1 to 10 of about 2,116 (170)

Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database [PDF]

Frontiers in Immunology
ObjectivesDupilumab and tralokinumab are FDA-approved biological agents for the treatment of atopic dermatitis (AD). This study analyzed tralokinumab-related adverse events (AEs) reported by healthcare professionals, utilizing data mined from the FDA ...
Yueping Jiang, Xinjuan Sun, Yang Li
doaj   +3 more sources

Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial [PDF]

Dermatology and Therapy
Introduction Tralokinumab is approved for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged ≥ 12 years. Here, we examined clinical laboratory parameters in adolescents with moderate-to-severe AD who were treated with ...
Amy S. Paller, Michael J. Cork, H. Chih-ho Hong, Weily Soong, Shannon K. R. Schneider, Hannah Lo, Frank Vinther, Patrick Thøgersen, Andreas Wollenberg   +8 more
doaj   +3 more sources

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis

Journal of Dermatological Treatment
Background: Injection site reaction (ISR) is a local phenomenon defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection.Objective: ISR is reported as a frequent adverse event after ...
Maddalena Napolitano
exaly   +4 more sources

Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis [PDF]

Journal of Comparative Effectiveness Research
Background: Atopic dermatitis (AD) is a chronic and burdensome condition that causes intense itching and painful skin lesions and affects around 10% of adults and adolescents across the US.
Reece Grindley, Linnea Houde, Aseel Bin Sawad, Sanjeev Balu, Shannon Schneider   +4 more
doaj   +2 more sources

Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease, and patients with moderate-to-severe AD may require treatment with biologics in combination with topical corticosteroids (TCS).
Marni Wiseman, Marco Benvenuto, Liv Strømkjær, Asger Paludan-Müller, Lasse Ryttig, Anne Sohrt Petersen, Andreas Wollenberg   +6 more
doaj   +2 more sources

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic skin disease largely driven by interleukin (IL)-13, which is targeted by tralokinumab and lebrikizumab.
Matthias Augustin, April Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres   +6 more
doaj   +2 more sources

Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data

Frontiers in Pharmacology
BackgroundTralokinumab, a humanized monoclonal antibody targeting interleukin-13, has been primarily used for the treatment of moderate-to-severe atopic dermatitis.
Kaidi Zhao, Shengxiang Xiao, Chen Tu
exaly   +3 more sources

Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis

Journal of Dermatological Treatment, 2023
Purpose: Although psoriasis and atopic dermatitis (AD) were for decades considered to be opposing diseases, it is now known that these skin conditions can coexist or even overlap in the same individual. Especially when using modern drugs with targeted IL
Silke Hofmann, Galina Balakirski, Alexander Kreuter   +2 more
exaly   +2 more sources

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring continuous therapy. The objective with the ECZTEND trial was to assess the long-term safety and efficacy of tralokinumab treatment.
Andrew Blauvelt, H. Chih-Ho Hong, Norito Katoh, Richard G. Langley, Vivian Laquer, Aleksandra Lesiak, Ketty Peris, Julien Seneschal, Juan-Francisco Silvestre, Richard B. Warren, Andreas Wollenberg, Matthew Zirwas, Niels Højsager Bennike, Farzaneh Safavimanesh, Ann-Marie Tindberg, Kristian Reich   +15 more
doaj   +2 more sources

Real‐life case‐series experience with tralokinumab in patients with severe atopic dermatitis

JEADV Clinical Practice
Atopic dermatitis (AD) is an inflammatory chronic recurrent skin condition that causes recurrent, itching eczematous lesions with a great impact on the quality of life of patients.
Francesca Caroppo
exaly   +2 more sources